Return to Results

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

new search

Trial Conditions
  • Idiopathic Pulmonary Fibrosis
What is the purpose of this trial?

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

Date & Status

Recruiting

Who can Participate?

Eligibility

Ages:
40  - 80 

Gender:
Both

Eligibility

Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. Diagnosis of IPF as defined by current international guidelines (Raghu, 2011). Each
subject must have one of the following: (1) Usual Interstitial Pneumonia (UIP)
Pattern on an available HRCT scan; or (2) Possible UIP Pattern on an available HRCT
scan and surgical lung biopsy within 4 years of Screening showing UIP Pattern.

3. History of IPF of ≤5 years duration with onset defined as the date of the first
diagnosis of IPF by HRCT or surgical lung biopsy.

4. Interstitial pulmonary fibrosis defined by HRCT scan at Screening, with evidence of
≥10% to <50% parenchymal fibrosis (reticulation) and <25% honeycombing, within the
whole lung, as determined by the HRCT central reader.

5. FVC percent of predicted value ≥55% at Screening.

6. Female subjects of childbearing potential (including those <1 year postmenopausal)
must be willing to use a medically acceptable method of contraception, for example,
an oral contraceptive, depot progesterone, or intrauterine device. Male subjects with
female partners of childbearing potential who are not using birth control as
described above must use a barrier method of contraception (e.g., condom) if not
surgically sterile (i.e., vasectomy).

7. All subjects in Arm A whose FVC percent predicted value is greater than the original
pre-treatment baseline in the Randomized Treatment Period will be offered
participation in an Extended Treatment Period

8. All subjects assigned to Placebo (Arm B) will be offered participation in the
Extended Treatment Phase.

Exclusion Criteria:

1. Women who are pregnant or nursing.

2. Infiltrative lung disease other than IPF, including any of the other types of
idiopathic interstitial pneumonias (Travis, 2013); lung diseases related to exposure
to fibrogenic agents or other environmental toxins or drugs; other types of
occupational lung diseases; granulomatous lung diseases; pulmonary vascular diseases;
systemic diseases, including vasculitis and connective tissue diseases.

3. HRCT scan findings at Screening are inconsistent with UIP Pattern, as determined by
the HRCT central reader.

4. Pathology diagnosis on surgical lung biopsy is anything other than UIP Pattern, as
determined by the local pathologist.

5. The Investigator judges that there has been sustained improvement in the severity of
IPF during the 12 months prior to Screening, based on changes in FVC, diffusing
capacity of the lung for carbon monoxide (DLCO), and/or HRCT scans of the chest.

6. Clinically important abnormal laboratory tests.

7. Upper or lower respiratory tract infection of any type within 4 weeks of the first
screening visit.

8. Acute exacerbation of IPF within 3 months of the first screening visit.

9. Use of medications to treat IPF within 5 half-lives of Day 1 dosing. If monoclonal
antibodies were used, the last dose of the antibody must be at least 4 weeks before
Day 1 dosing.

10. Use of any investigational drugs, including any investigational drugs for IPF, within
4 weeks prior to Day 1 dosing.

11. History of cancer diagnosis of any type in the 3 years preceding Screening, excluding
non-melanomatous skin cancer, localized bladder cancer, or in situ cancers

12. Diffusing capacity (DLCO) less than 30% of predicted value

13. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine
monoclonal antibodies.

14. Previous treatment with FG-3019.

15. Body weight greater than 130 kilograms.

Gender: Both
Steward Physician(s)
  • Mark Wencel, M.D
  • Joao de Andrade, M.D
  • Peter LaCamera, M.D.
  • Danielle Antin-Ozerkis, M.D.
  • Rishi Raj, M.D.
  • Neil Ettinger, M.D
  • Rafael Perez, M.D
  • Timothy Albertson, M.D
  • Yolanda Mageto, M.D.
  • Srihari Veeraraghavan, M.D
  • Nishant Gupta, M.D
  • Daniel Kass, M.D
  • Lisa Lancaster, M.D.
  • Mary Scholand, M.D.
  • Jonathan Ruzi, M.D.
  • Mark Hamblin, M.D.
  • Leslie Tolle, M.D.
  • John Fitzgerald, M.D.
  • John Belperio, M.D.
  • Richard Enelow, M.D.
  • Evans R Fernandez-Perez, M.D
  • Peter A Bercz, M.D
  • Krishna Thavarajah, M.D.
  • James Britt, M.D.
  • Danielle D. Hosmer
Facilities
  • St. Elizabeth's Medical Center - Recruiting
Trial Interventions
Drug
  • FG-3019
  • Placebo
For more information about this trial, contact

Peter LaCamera, M.D.
peter.lacamera@steward.org
Phone: (617) 789-2078


Physician Researcher

Investigator Name:

  • Mark Wencel, M.D
  • Joao de Andrade, M.D
  • Peter LaCamera, M.D.
  • Danielle Antin-Ozerkis, M.D.
  • Rishi Raj, M.D.
  • Neil Ettinger, M.D
  • Rafael Perez, M.D
  • Timothy Albertson, M.D
  • Yolanda Mageto, M.D.
  • Srihari Veeraraghavan, M.D
  • Nishant Gupta, M.D
  • Daniel Kass, M.D
  • Lisa Lancaster, M.D.
  • Mary Scholand, M.D.
  • Jonathan Ruzi, M.D.
  • Mark Hamblin, M.D.
  • Leslie Tolle, M.D.
  • John Fitzgerald, M.D.
  • John Belperio, M.D.
  • Richard Enelow, M.D.
  • Evans R Fernandez-Perez, M.D
  • Peter A Bercz, M.D
  • Krishna Thavarajah, M.D.
  • James Britt, M.D.
  • Danielle D. Hosmer

Other Information

Sponsor: FibroGen
Phase: Phase 2
Trial ID: NCT01890265
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions